![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Active Filter(s):
Details:
Proceeds from the financing will be used to further build Engimmune’s pipeline having T-cell receptor based therapies, expand the research team in Switzerland, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
Lead Product(s): T-cell Receptor Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pureos Bioventures
Deal Size: $16.7 million Upfront Cash: Undisclosed
Deal Type: Financing May 03, 2022